Research theme for competitive and other funds (2):
2020 - 2023 ニューロメジンB受容体拮抗薬はクッシング病の新規治療薬となるか
2019 - 2020 Neuromedin B receptor antagonist as a new treatment for Cushing disease
Papers (310):
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, Yuka Suzuki, Atsushi Tsuzuki, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, et al. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study). Diabetes, obesity & metabolism. 2024. 26. 3. 961-970
Rimi Izumihara, Hiroshi Nomoto, Kenichi Kito, Yuki Yamauchi, Kazuno Omori, Yui Shibayama, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, et al. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease. Diabetes & metabolism journal. 2024
Akinobu Nakamura, Aika Miya, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Tatsuya Atsumi. Positive association between proinsulin and fatty liver index in people with type 2 diabetes. Endocrine journal. 2024. 71. 2. 193-197
Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi. Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocrine journal. 2024
Hiroshi Iesaka, Hiraku Kameda, Aika Miya, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Takashige Abe, Nobuo Shinohara, Tatsuya Atsumi. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report. Medicine. 2023. 102. 51. e36664